利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

373 条记录 (耗时 0.042 秒)

    Growth hormone-releasing peptides and method of treating animals, therewith
    131.
    发明授权
    Growth hormone-releasing peptides and method of treating animals, therewith 失效
    生长激素释放肽和治疗动物的方法

    公开(公告)号：US5416073A

    公开(公告)日：1995-05-16

    申请号：US807821

    申请日：1985-12-16

    申请人： David H. Coy ,  William A. Murphy

    发明人： David H. Coy ,  William A. Murphy

    IPC分类号： A61K38/00 ,  C07K14/60 ,  A61K38/27 ,  C07K7/00

    CPC分类号： C07K14/60 ,  A61K38/00

    摘要： The present invention relates to novel growth hormone-releasing peptides and method for increasing the release of growth hormone levels in mammals, as well as method for increasing milk production in dairy cows and increasing growth rates of animals, such as cattle, sheep, swine, and others. The novel peptides of this invention surprisingly are effective for releasing growth hormone levels in animals by replacing the natural amino acids in positions 1, 2, 3, 8, 9, 10, 12, 21 and 27, as well as derivatizing the N-terminal amino acid residue in human pancreatic islet tumor origin growth hormone-releasing factor.

    摘要翻译： 本发明涉及新型生长激素释放肽和增加哺乳动物生长激素水平释放的方法，以及增加奶牛产奶量和增加动物如牛，绵羊，猪， 和别的。 本发明新颖的肽令人惊奇的是通过替代1,2,3,4,8,9,10,12,21和27位的天然氨基酸以及衍生N末端有效释放动物中的生长激素水平 人胰岛细胞中的氨基酸残基起源于生长激素释放因子。

    Cardiovascular flow enhancer and method of operation
    132.
    发明授权
    Cardiovascular flow enhancer and method of operation 失效
    心血管流量增强剂及其操作方法

    公开(公告)号：US5267940A

    公开(公告)日：1993-12-07

    申请号：US695946

    申请日：1991-05-06

    申请人： Peter V. Moulder

    发明人： Peter V. Moulder

    IPC分类号： A61F2/06 ,  A61M1/10 ,  A61M1/12 ,  A61M39/22 ,  A61F2/00 ,  A61N1/362

    CPC分类号： A61F2/06 ,  A61M1/10 ,  A61M1/1005 ,  A61M1/101 ,  A61M1/1018 ,  A61M1/122 ,  A61M1/12 ,  A61M2205/3337 ,  A61M39/228

    摘要： An implanted cardiovascular assist pump is connected with the proximal descending thoracic aorta. The pump inlet is connected with the aorta at substantially the site of the first pressure/flow node from the heart. The pump outlet is connected at substantially the site of the last pressure/flow antinode before the heart. Control of pump speed varies blood flow through the pump. As a fail-safe mechanism, a pump shunt flow path is provided, through one of a variety of disclosed structures.

    摘要翻译： 植入式心血管辅助泵与近端下行胸主动脉连接。 泵入口与心脏在基本上位于第一压力/流动节点的位置处与主动脉连接。 泵出口基本上连接在心脏之前的最后一个压力/流量波腹部位。 泵速度的控制改变了通过泵的血液流量。 作为故障保护机构，通过各种公开的结构之一提供泵分流流动路径。

    Therapeutic decapeptides
    133.
    发明授权
    Therapeutic decapeptides 失效
    治疗十肽

    公开(公告)号：US5003011A

    公开(公告)日：1991-03-26

    申请号：US421245

    申请日：1989-10-13

    申请人： David H. Coy ,  Jacques-Pierre Moreau

    发明人： David H. Coy ,  Jacques-Pierre Moreau

    IPC分类号： A61K38/00 ,  C07K7/06 ,  C07K7/23

    CPC分类号： C07K7/06 ,  C07K7/23 ,  A61K38/00 ,  Y10S514/80 ,  Y10S514/885

    摘要： A decapeptide of the formula:N-Ac-A.sup.1 -A.sup.2 -A.sup.3 -SER.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9 -A.sup.10,wherein each A.sup.1, A.sup.2, and A.sup.3, independently, is D-.beta.-Nal, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl); A.sup.5 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl); A.sup.6 is D-Lys, D-Arg, .beta.-Nal, D-.beta.-Nal, D-Trp, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl) or D-lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sup.7 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, C.sub.2 F.sub.5, or C.sub.1-3 alkyl), cyclohexyala, or Trp; A.sup.8 is Arg, Lys, or Lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl croup); A.sup.9 is Pro; and A.sup.10 is D-Ala-NH.sub.2, Gly-NH.sub.2, D-Ser, or D-Ser-NH.sub.2 ; provided that at least one of A.sup.2 or A.sup.3 must be D-Phe or D-Tyr; and further provided that one or both of A.sup.6 and A.sup.8 must be the following: A.sup.6 must be D-Lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sup.8 must be Lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl group), or a pharmaceuticaly acceptable salt thereof.

    摘要翻译： 具有下式的十肽：N-Ac-A1-A2-A3-SER4-A5-A6-A7-A8-A9-A10，其中每个A1，A2和A3独立地是D-β-Nal，DpX- Phe（其中X为卤素，H，NH 2，NO 2，OH或C 1-3烷基）; A5是p-X-Phe（其中X是卤素，H，NH 2，NO 2，OH或C 1-3烷基）; A6是D-Lys，D-Arg，β-Nal，D-β-Nal，D-Trp，DpX-Phe（其中X是卤素，H，NH 2，NO 2或C 1-3烷基）或D-lys- ε--NH-R（其中R是H，支链或直链或环C 1 -C 10烷基或芳基）; A7是p-X-Phe（其中X是卤素，H，NH2，NO2，OH，C2F5或C1-3烷基），环己烯或Trp; A8是Arg，Lys或Lys-ε--NH-R（其中R是H，支链或直链或环C1-C10烷基或芳基）。 A9是Pro A10为D-Ala-NH2，Gly-NH2，D-Ser或D-Ser-NH2; 条件是A2或A3中的至少一个必须是D-Phe或D-Tyr; 并且进一步规定A6和A8之一或两者必须为：A6必须为D-Lys-ε--NH-R（其中R为H，支链或直链或环C1-C10烷基或芳基 组）; A8必须是Lys-ε--NH-R（其中R是H，支链或直链或环C1-C10烷基或芳基）或其药学上可接受的盐。